A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT06284486
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
12 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To learn if the combination of venetoclax and revumenib can help to control MRD-positive AML.

Key Dates

Start date
Sep 23, 2024
Status verified
Apr 2026
Primary completion
Dec 30, 2026
Completion
Dec 30, 2028

Study Design

Enrollment
8 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Venetoclax + Revumenib
    Participants may receive the combination of venetoclax and revumenib for up to 1 year, and then 1 more year of venetoclax alone. You will no longer be able to take the study drug(s) if the disease gets worse or if intolerable side effects occur. Participants will take venetoclax by mouth on 1 time a day at about the same time each day, on Days 1-14 of each cycle. Take each dose with about 1 cup of water within 30 minutes after a meal, preferably breakfast.

Primary Outcome Measure

Safety and adverse events (AEs) [ Time Frame: Through study completion; an average of 1 year. ]

Central Contacts

Locations (4)

FacilityCityStateZIPSite coordinators
Johns Hopkins UniversityBaltimoreMaryland21218
Alexander Ambinder, MD
[email protected]
Dana-Farber Cancer CenterBostonMassachusetts02215
Jacqueline Garcia, MD
[email protected]
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065
Aaron Goldberg, MD
[email protected]
646-608-3752
Aaron Goldberg, MD (PRINCIPAL_INVESTIGATOR)
MD Anderson Cancer CenterHoustonTexas77030
Ghayas Issa, MD
[email protected]
713-745-6798
Ghayas Issa, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Baltimore, MD

By condition
Leukemia (other)
By specialty
OncologyBlood cancer
By research site
Johns Hopkins University· Baltimore, MDDana-Farber Cancer Center· Boston, MAMemorial Sloan Kettering Cancer Center· New York, NYMD Anderson Cancer Center· Houston, TX

Related Studies